Stockscreener 앱 받기
0.70
7.03%
0.046
시간 외 거래:
.71
0.01
+1.43%
전일 마감가:
$0.654
열려 있는:
$0.6681
하루 거래량:
4.88M
Relative Volume:
0.75
시가총액:
$43.40M
수익:
-
순이익/손실:
$-22.83M
주가수익비율:
-0.8861
EPS:
-0.79
순현금흐름:
$-20.87M
1주 성능:
+15.70%
1개월 성능:
+174.51%
6개월 성능:
-5.41%
1년 성능:
-61.96%
1일 변동 폭
$0.6681
$0.71
1주일 범위
$0.5525
$0.71
52주 변동 폭
$0.2223
$2.535
Cognition Therapeutics Inc Stock (CGTX) Company Profile
명칭
Cognition Therapeutics Inc
전화
412-481-2210
주소
2403 SIDNEY STREET, PITTSBURGH
CGTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.70 | 37.51M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 개시 | B. Riley Securities | Buy |
| 2021-11-03 | 개시 | Oppenheimer | Outperform |
Cognition Therapeutics Inc 주식(CGTX)의 최신 뉴스
Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire
Cognition Therapeutics reports positive results for Alzheimer’s drug - Investing.com India
Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times
Breakthrough: New Alzheimer's Drug Protects Brain Cells from Death, Phase 2 Study Reveals - Stock Titan
Is Cognition Therapeutics Inc. a good long term investmentRapidly growing investment returns - PrintWeekIndia
Cognition Therapeutics Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional
What drives Cognition Therapeutics Inc. stock priceSkyrocketing returns - Autocar Professional
What analysts say about Cognition Therapeutics Inc. stockExceptional ROI - jammulinksnews.com
How high can Cognition Therapeutics Inc. stock price go in 2025Free Stock Market Forecasting Tools - beatles.ru
Dementia Associated with Alzheimer’s Disease Drug - GlobeNewswire
Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com
Cognition Therapeutics stock soars after DLB study results - Investing.com
Cognition Therapeutics stock soars after DLB study results By Investing.com - Investing.com South Africa
CGTX Soars 19.72% on Promising Dementia Drug Results - AInvest
Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq
Cognition Therapeutics' Positive Clinical Data from - GlobeNewswire
Breakthrough DLB Treatment: Clinical Trial Reveals 86% Symptom Improvement in Dementia Patients - Stock Titan
Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com
How Cognition Therapeutics Inc. stock performs during market volatilityMomentum Buy Alert - Newser
Why Cognition Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser
What makes Cognition Therapeutics Inc. stock price move sharplyFree High-Profit Stock Picks - Newser
Cognition Therapeutics shares fall 1.16% premarket after Karolinska Development's portfolio company Umecrine Cognition raises SEK 24.6 million for clinical development. - AInvest
CGTX’s 2025 Market Saga: Unraveling the Story of Gains and Losses - investchronicle.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of “Buy” from Analysts - Defense World
Cognition Therapeutics (NASDAQ:CGTX) Rating Lowered to Strong Sell at Wall Street Zen - Defense World
Cognition Therapeutics: Clinical Milestones Ignite Potential in Neurodegenerative Therapeutics - AInvest
Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress - Yahoo Finance
Cognition Therapeutics, Inc. (CGTX) Plunges 14.29% Amid FDA Meeting Outcome - AInvest
Cognition Therapeutics shares fall 10.57% in premarket after FDA meeting on zervimesine for Alzheimer's treatment. - AInvest
Cognition Therapeutics completes FDA end-of-Phase 2 meeting for Alzheimer’s drug By Investing.com - Investing.com South Africa
Cognition Therapeutics Inc. (CGTX) Soars 31.45% on FDA Phase 3 Trial Approval - AInvest
Cognition Therapeutics completes FDA end-of-Phase 2 meeting for Alzheimer’s drug - Investing.com Nigeria
Cognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesine - Seeking Alpha
Cognition Therapeutics stock soars after FDA meeting on Alzheimer’s drug - Investing.com
Cognition Therapeutics stock soars after FDA meeting on Alzheimer’s drug By Investing.com - Investing.com South Africa
Cognition Therapeutics Conducts Meeting With US FDA to Review Phase 2 Study Results of Zervimesine - MarketScreener
Cognition Therapeutics Soars 61.65% on Positive FDA Meeting - AInvest
Cognition Therapeutics: Zervimesine Emerges as Alzheimer's Breakthrough with FDA Backing and NIH Support - AInvest
Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA - Nasdaq
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease - GlobeNewswire
Breakthrough for Alzheimer's Treatment: FDA Meeting Clears Path for Zervimesine Phase 3 Program - Stock Titan
Cognition Therapeutics (CGTX) Soars 12% After-Hours on Alzheimer's Trial Data - AInvest
Cognition Therapeutics Inc (CGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):